NEW YORK (GenomeWeb) – Quidel reported after the close of the market on Tuesday that its first quarter revenues rose 130 percent year over year, primarily driven by incremental revenues from an acquired cardiac immunoassay business and sales of influenza immunoassay products.

For the three months ended March 31, revenues rose to $169.1 million from $73.7 million in Q1 2017, and beating the average analysts' estimate of $150.9 million.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Publication of He Jiankui's work on gene-edited infants would raise ethical concerns for journals, Wired and others report.

The New York Times reports that evidence linking trauma in one generation to epigenetic effects that influence subsequent generations may be overstated.

ScienceInsider reports that US National Institutes of Health researchers were told in the fall they could not obtain new human fetal tissue.

In PNAS this week: skin pigmentation evolution among KhoeSan, biomarkers for dengue virus progression, and more.